Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2021 call → NOWe need answer only YES or NO. Need determine if management describes successive engagements of same kind coming in at progressively larger size. Need analyze transcript. We need look for evidence: deals/orders/contracts/projects/customers/sites/programs landing now individually bigger/broader/longer than before for same offering. Management's own words. Transcript: Hello Group (Momo, Tantan). Discusses Q3 2021. Key topics: core Momo user growth, live streaming, VAS, Tantan user growth, new apps (Sochio, etc.). Need see if any statement about unit size escalating. Possible: Sochio revenue growth driven by user base and ARPPU expansion. Paying users increased 50% compared to beginning of year, ARPPU more than doubled. That is not about successive engagements of same kind? It's about ARPPU (average revenue per paying user) increasing. But is that "unit size of repeatable business escalating"? ARPPU is per user, not necessarily deals. Could be monetization per user increasing. But question asks "deals, orders, contracts, projects, customers, sites, or programs" - for social apps, "customers" maybe paying users. But "successive engagements of the same kind" - not really. Management says Sochio generated robust revenue growth driven by both user base and ARPPU expansion. ARPPU more than doubled over same period. That is average revenue per paying user increasing, which could be interpreted as each customer paying more. But is that "landing now individually bigger" than before? It's same offering (voice social app) and ARPPU increased. But is it a comparison against company's own recent past? Yes, ARPPU more than doubled since beginning of year. Already real and recurring? It's current. Early? They plan continue invest. But is this "successive engagements of same kind" - paying users are customers, and ARPPU is average revenue per user. However, the question specifically asks about "deals, orders, contracts, projects, customers, sites, or programs" - for subscription/app, customers paying more could be analogous to larger deals. But need be careful: ARPPU increase could be due to price increase or mix, not necessarily larger unit size. Management says "stepped up marketing efforts, targeting high-value users.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.